PER

3.57%

8.7¢ percheron therapeutics limited

@cdoyle Thanks With reference to Charmaine's role if the chair...

First 24 Last

Share
Profile

Follow
samfiodiving

4,103 Posts.

1866

05/10/21

14:36

Post #: 56575859
Share

Originally posted by cdoyle ↑

Great post sam, love the charts, insights and the open questions you pose. But I disagree on one point.

It would be a very hard decision as a board to replace Mark as the CEO as he is, from what you have posted above, doing most things right and getting what I believe to be the most important things right (the science progression). Getting Charmaine in the company in any capacity was the right move. As chairman(woman?), she is someone that Mark would go to for advice, and guide his decisions and define long term strategy. Something that right now is most critical time ANP's history as partnerships/ funding and go to market strategies are almost within grasp. And hopefully support in getting the market penetration we need.

From Charmaine's linkedin "proven track record of executive leadership competence, decision making and strategic thinking. ...had accountability for clinical research, medical safety, medical ethics and patient matters for all development programs and on market products, providing leadership in strategic product development, planning and implementation across multiple therapeutic areas. Under my oversight of the clinical group the company had an unprecedented run of five major product approvals and launches within a 24-month period."

To me, that experience sounds better as someone who is deciding the long term strategy and is thinking beyond the day to day operations. Marks got 20 years as CEO in ANP, is that experience someone you want to get rid of? Or rather get someone to guide him over the finish line?

It surprises me that with all of the recent research reports the shareprice hasn't moved and agree there is something amiss. However, we must ask ourselves, what would 10 more investor road shows done in the past year? Shareprice would be 5x what it is now? And then what? It's more expensive for us to buy I suppose. Or we have have had a partner already who injected more money in the coffers? But then what would we have done with that without the ability to progress into a clinical trial? Maybe a buyout from pharma and made 10 bags? Would it be better to be in a clinical trial or completed one then be bought out having demonstrated maximum value?

For me, I've enjoyed continuing to accumulate at these levels and will do so for a while to go; but feel that the price we can do so at will be far more expensive soon.

Expand

@cdoyle
Thanks
With reference to Charmaine's role if the chair were to present i wouldn't have a problem

Not sure how long you have been around ANP

But with your ref

Marks got 20 years as CEO in ANP, is that experience someone you want to get rid of?

I won't touch that one all long termers know my position with regards to that question but don't want to trash the forum

Your last post with ref to roadshows doesn't make sense ,why i we here if not to advance our investment

We have already had a partner that injected funds to the tune of $10mil overall

Go back and see the progression with those funds

Sorry mate i don't want to go on so will leave it at that

I respect your opinion and wish you well with your investment

Cheers

ANP Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

HLX

Helix investor makes partial takeover bid, proposing board changes

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

There are more pages in this discussion • 14 more messages in this thread...

First 24 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.7¢		Change 0.003(3.57%)		Mkt cap ! $78.43M

Open	High	Low	Value	Volume
8.4¢	8.7¢	8.4¢	$72.99K	855.8K

Buyers (Bids)

No.	Vol.	Price($)
2	452608	8.4¢

Sellers (Offers)

Price($)	Vol.	No.
8.7¢	398595	1

View Market Depth

No.	Vol.	Price($)
2	452608	0.084
3	212500	0.083
2	106250	0.080
2	125578	0.079
1	12462	0.078

Price($)	Vol.	No.
0.087	398595	1
0.088	400000	1
0.089	135000	2
0.090	794374	5
0.092	50000	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

PER (ASX) Chart

@cdoyle Thanks With reference to Charmaine's role if the chair...

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Lendlease sells off US east coast construction operations in latest global divestment push

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Helix investor makes partial takeover bid, proposing board changes

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

@cdoyle Thanks With reference to Charmaine's role if the chair...

Top Stories

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Lendlease sells off US east coast construction operations in latest global divestment push

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Helix investor makes partial takeover bid, proposing board changes

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News